Article précédent Article suivant

The French Competition Authority fines 3 laboratories for abusive efforts to segment market (Novartis / Roche / Genentech)

Background On 9 September 2020, the French Competition Authority (the “FCA”) imposed a fine of € 444 million on Genentech, Novartis and Roche for abusing their collective dominant position on the market for the commercialisation of drugs for the treatment of age-related macular degeneration (AMD) (an eye condition). The FCA’s decision concerned two virtually-identical products developed and manufactured by Genentech (a subsidiary of Roche): (i) Avastin - a lower-priced product indicated for the treatment of certain forms of cancer, and (ii) Lucentis - a higher-priced product indicated for the treatment of certain eye diseases, including AMD. For commercialisation purposes, Genen- tech licensed Lucentis to Novartis (which owns 33.3% of Roche), whilst Avastin was to be commercialised by

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • Van Bael & Bellis (Brussels)

Citation

Samuel Hall, The French Competition Authority fines 3 laboratories for abusive efforts to segment market (Novartis / Roche / Genentech), 9 septembre 2020, e-Competitions Preview, Art. N° 97142

Visites 17

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues